Capricor Therapeutics is trading 10.59% up now at $7.83 as biotechnology shares rally broadly.
- Investors await the August 22 FDA decision for deramiocel; the company’s BLA remains under active FDA review.
- Positive HOPE-3 data continue supporting optimism around the therapy.
- An August 19 shareholder-litigation alert adds negative legal context but does not explain today’s gain; regulatory-event positioning provides additional support.